BYOMass Inc.

BYOMass is a preclinical pharmaceutical company that develops biologic and small molecule drugs targeting specific members of the TGF-β superfamily. The company focuses on modulating these pathways to address orphan and common diseases, with potential therapeutic applications in oncology, inflammatory, immune, fibrotic, and metabolic conditions. Founded by V. Margaret Jackson, the company employs a pathway-driven, scientific approach to drug discovery, combining the expertise of an experienced pharmaceutical leadership team with the agile operational structure of a startup to advance novel candidates through preclinical stages.

This work is critical for patients suffering from conditions with high unmet medical needs where traditional therapies have been ineffective. By employing systems pharmacology modeling and mechanistic research, BYOMass aims to de-risk its pipeline and optimize the development of its lead candidates. The company collaborates with organizations such as Applied BioMath to refine its therapeutic platforms and has engaged industry experts to its board of directors to support its mission of bringing transformative treatments from early-stage research toward clinical development.